All results - Drugs and Technologies - Prescribing and Technical Information - Safety Alerts - Medicines and Healthcare products Regulatory Agency - MHRA - British Association of Dermatologists - BAD | Evidence search

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Hirzia 100mg Tablets - UK/H/890/01/MR; PL 00101/0698 [PDF]

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 09 October 2007 - Publisher: MHRA;Gov UK

This is just the first MHRA Public Assessment Report from your search. See all

RESTRICTED COMMERCIAL UK/H/887-890/01/MR MHRA; Prexige/Frexocel/Stellige/Hirzia 100 Tablets MRPAR 1 Public Assessment Report Mutual Recognition

Remove: Prescribing and Technical Information filter
Letters sent to healthcare professionals in August 2017

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 26 September 2017 - Publisher: Medicines and Healthcare products Regulatory Agency

Letters were sent about INOmax (nitric oxide) cylinders and triptorelin (Decapeptyl).

Read Summary

- Remove: Prescribing and Technical Information filter
Medical Device Alerts issued in August 2017

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 26 September 2017 - Publisher: Medicines and Healthcare products Regulatory Agency

Alerts were issued about NovoPen Echo and NovoPen 5 insulin pens and BioMérieux antimicrobial susceptibility tests.

Read Summary

- Remove: Prescribing and Technical Information filter
Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 30 August 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for...

Read Summary

- UKMi comment

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 July 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

MHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach; remind patients to take 15 mg or 20...

Read Summary

- UKMi comment

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 July 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be measured before starting treatment with tocilizumab and monitored every 4–8 weeks for the first 6 months of...

Read Summary

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 July 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

Avoid treatment with febuxostat in patients with pre-existing major cardiovascular disease (for example, myocardial infarction, stroke, or unstable angina), unless no other therapy options are...

Read Summary

- UKMi comment

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 19 June 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

New prescriber checklists, patient reminder cards, and pharmacy checklists are available to support the Pregnancy Prevention Programme in women taking acitretin, alitretinoin, and isotretinoin.

Read Summary

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 19 June 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

Diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued.

Read Summary

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter
Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 19 June 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

A clinical trial has shown an increased risk of recurrent thrombotic events associated with rivaroxaban compared with warfarin, in patients with antiphospholipid syndrome and a history of thrombosis.

Read Summary

- Remove: Prescribing and Technical Information filter

- Remove: Safety Alerts filter

Filter results by

Results for all evidence | Drugs and Technologies | Prescribing and Technical Information | Medicines and Healthcare products Regulatory Agency - MHRA 1 - 10 of 1038 sorted by relevance / date

Hirzia 100mg Tablets - UK/H/890/01/MR; PL 00101/0698 [PDF]

Letters sent to healthcare professionals in August 2017

Medical Device Alerts issued in August 2017

Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food

Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation

Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease

Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued

Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome